Analogously, KRAS inhibitors (Sotorasib) targeting the G12C mutation and eprenetapopt (APR-246), a novel drug for Tp53-mutant MDS and AML, both are representatives of this molecules. This evidence concerns the gene KRAS and acute myeloid leukemia.